Datopotamab Deruxtecan-Based Combinations Show Promising Clinical Activity in Patients with Advanced Non-Small Cell Lung Cancer
Late-breaking oral presentation at WCLC features first results from TROPION-Lung02 trial of Daiichi Sankyo and AstraZeneca’s TROP2 directed antibody drug conjugate TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Initial results from the TROPION-Lung02 phase 1b trial showed that datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy demonstrated promising clinical activity and a tolerable … [Read more…]
